Today: 29 June 2026
Browse Category

NASDAQ:MRNA 23 January 2026 - 28 June 2026

US stocks look to jobs data as traders shift from AI tech

US stocks look to jobs data as traders shift from AI tech

Semiconductor stocks plunged 7.9% last week, their worst performance since April, dragging the S&P 500 down 2.05% as investors pulled nearly $20 billion from tech funds; strategists warn that continued weakness in mega-cap tech could weigh on cap-weighted indexes even as smaller stocks rally, with upcoming jobs data and rate expectations posing further risks.
28 June 2026
·········
Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

Moderna soared 12.6% Friday on heavy volume after unveiling new in vivo CAR-T pipeline plans, closing at $67.27—52% above the mean analyst target but still 14.5% below Piper Sandler’s new $77 target. The rally followed Science Day updates, even as analysts note the main new asset is preclinical and cash burn continues, with $7.5B cash at March-end and a projected $3B R&D spend for 2026.
27 June 2026
··
US futures edge lower ahead of Russell index reshuffle as chip stocks see selling

US stocks: After-hours chips slump overshadows gains ahead of jobs data

PHLX chip index plunged 5.3% Friday and 7.9% for the week as surging memory costs hit device makers like Apple, driving $20 billion in tech fund outflows and raising inflation fears, while S&P 500 advancers outnumbered decliners and after-hours trading showed no clear tech rebound.
27 June 2026
············
Tech fund outflows hit US stocks after hours as AI trade momentum cools

Tech fund outflows hit US stocks after hours as AI trade momentum cools

Tech sector funds saw nearly $20 billion in weekly outflows, reversing last week’s record inflow, as the Nasdaq 100 slid 1.09% and chip stocks tumbled, with the PHLX semiconductor index down over 4% for its biggest weekly drop since March, raising fresh concerns for investors in large tech and chip names.
26 June 2026
·······
Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

Moderna surged 7.94% to $49.64 as U.S. stocks rebounded sharply, with investors eyeing its mRNA cancer-vaccine pipeline after a UK trial authorization; Wall Street’s average analyst rating remains “Hold” with a $43.30 target, and BofA raised its price target to $34 citing norovirus prospects, while Moderna reported Q1 revenue of $389 million and a $1.3 billion net loss.
11 June 2026
·
Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna’s early-stage hantavirus vaccine research drew renewed attention after a deadly Andes virus outbreak on the MV Hondius cruise ship, with six confirmed cases and three deaths reported. Moderna shares closed up nearly 12% Friday. WHO and ECDC rated the broader public risk as low, but recommended a 42-day quarantine for passengers. No approved vaccine or treatment for Andes virus exists, according to the CDC.
11 May 2026
··
Moderna Stock Surges on Hantavirus Vaccine Research as MRNA Investors Eye Flu and Cancer Pipeline

Moderna Stock Surges on Hantavirus Vaccine Research as MRNA Investors Eye Flu and Cancer Pipeline

Moderna confirmed early-stage research on hantavirus vaccines with U.S. Army and Korea University partners, following a deadly outbreak on the MV Hondius cruise ship. Eight cases, including three deaths, have been reported; six cases are confirmed. Moderna shares rose 11.9% to $54.35. Spain and several EU countries are preparing evacuations as the ship nears Tenerife.
9 May 2026
··
Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus

Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus

Moderna shares rose about 10% Friday after the company announced research into vaccines for hantaviruses amid a deadly Andes virus outbreak linked to the MV Hondius cruise ship. WHO reported eight cases and three deaths, with five confirmed as hantavirus. Moderna’s vaccine program is in early stages, with commercial availability still years away. The U.S. is arranging a repatriation flight for 17 Americans from the ship.
8 May 2026
·
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna’s first-quarter revenue jumped to $389 million, driven by international Covid vaccine sales, while U.S. revenue fell to $78 million. The company posted a net loss of $1.34 billion after a $900 million patent settlement charge. Shares fell 2.7% in early trading. Moderna kept its 2026 growth target and expects FDA action on its flu vaccine by August 5, 2026.
1 May 2026
·
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
15 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares fell 6.09% to $48.71 Friday after CEO Stéphane Bancel said the company will scale back new late-stage vaccine trials, citing U.S. resistance and policy delays. The drop followed a midweek rally on positive cancer vaccine data with Merck. Investors await Moderna’s Feb. 13 results for further updates. U.S. markets are closed until Monday.
24 January 2026
···
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·····
1 2 3 4

Stock Market Today

  • Soybeans Close Slightly Lower as Traders Reduce Long Positions Ahead of June Acreage Report
    June 28, 2026, 10:43 PM EDT. Soybeans ended Friday's session with minor losses, as July contracts expired and traders adjusted positions ahead of Tuesday's June Acreage report from USDA's National Agricultural Statistics Service (NASS). Speculators trimmed net long soybean positions by 16,139 contracts, mainly through exiting long positions. Cash bean prices declined 2.5 cents to $10.76 per bushel. Soymeal futures fell 40 cents, while soy oil front-month futures gained up to 49 points. Export sales remain strong, with old crop commitments matching USDA projections and new crop sales significantly higher than last year. Market watchers await NASS's report, which is expected to confirm 85.2 million acres planted this spring, potentially impacting prices and trade flows.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop